Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Merck KGaA Seals Record-Breaking $11.3B Deal for Bio-Techne

Guavy AI Editorial Team
Instruments
MRK
Share

Merck KGaA has cleared the final hurdle in its acquisition of Bio-Techne Corporation, a life science tools company. Shareholders voted in favor of the deal on September 23, 2026.

The all-cash transaction is valued at approximately USD 11.3 billion and represents Merck KGaA's largest deal since it purchased Sigma-Aldrich for USD 17 billion in 2015.

New CEO Kai Beckmann framed the acquisition as an 'important milestone' towards delivering on the company's strategic agenda, with the deal offering a premium of around 36% over Bio-Techne's average share price before announcement.

More on Stocks

Stocks just now

Microsoft Leaders Sued Over Rescue Deal for Gates and Hoffman

Stocks 1m ago

Nvidia Edges Out AMD as Top Chipmaker Amid AI Boom

Stocks 6m ago

$405M Visa Escrow Deposit Trims Class B Conversion Rates, Share Counts

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy